Ivonescimab plus chemotherapy for advanced bile duct or gallbladder cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called ivonescimab plus standard chemotherapy, compared to the usual chemo and immunotherapy (pembrolizumab or durvalumab), for people with advanced bile duct or gallbladder cancer. The goal is to see if the new combination helps patients live longer without the cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be able to get around and take care of yourself (Eastern Cooperative Oncology Group score of 0 or 1).
- You must have bile duct or gallbladder cancer that has spread or cannot be removed with surgery.
- You must not have had previous drug treatment (like chemo or immunotherapy) for this stage of your cancer. Prior chemo or radiation to help keep the cancer from coming back is okay if you've been cancer-free for more than 6 months after it.
- You must have normal enough blood counts and liver and kidney function as shown in recent blood tests.
- You must not have had recent major surgery, bleeding problems, high blood pressure that is not controlled, or certain autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination given before surgery to shrink bile duct cancer tumors, potentially making surgery more successful. It is for patients whose cancer is locally advanced or has spread to only a few places.
This study tests a combination of three drugs (ivonescimab, liposomal irinotecan, and 5-FU/LV) in people with bile duct or gallbladder cancer that hasn't been treated yet. The goal is to shrink the tumor enough so that it can be removed with surgery.
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
Hear when a new Locally Advanced Biliary Tract Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.